Pharma Current Deferred Revenue from 2010 to 2024
| 0RC6 Stock | 75.72 2.97 4.08% |
Current Deferred Revenue | First Reported 2009-06-30 | Previous Quarter 15 M | Current Value 10 M | Quarterly Volatility 15.9 M |
Check Pharma Mar financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharma Mar's main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.1 M, Selling General Administrative of 19.9 M or Total Revenue of 146.3 M, as well as many indicators such as . Pharma financial statements analysis is a perfect complement when working with Pharma Mar Valuation or Volatility modules.
Pharma | Current Deferred Revenue |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pharma Stock Analysis
When running Pharma Mar's price analysis, check to measure Pharma Mar's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Mar is operating at the current time. Most of Pharma Mar's value examination focuses on studying past and present price action to predict the probability of Pharma Mar's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Mar's price. Additionally, you may evaluate how the addition of Pharma Mar to your portfolios can decrease your overall portfolio volatility.